Levy, M., Bahlis, N., Raje, N., Costello, C., Dholaria, B., Solh, M., … Lesokhin, A. (2021). MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM). In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 21, pp. S439–S439).

Levy, Moshe, Nizar Bahlis, Noopur Raje, Caitlin Costello, Bhagirathbhai Dholaria, Melhem Solh, Michael Tomasson, et al. “MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM).” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 21:S439–S439, 2021.

Levy M, Bahlis N, Raje N, Costello C, Dholaria B, Solh M, et al. MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM). In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2021. p. S439–S439.

Levy, Moshe, et al. “MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM).” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 21, 2021, pp. S439–S439.

Levy M, Bahlis N, Raje N, Costello C, Dholaria B, Solh M, Tomasson M, Dube H, Damore M, Lon HK, Basu C, Skoura A, Chan E, Trudel S, Jakubowiak A, Chu M, Gasparetto C, Dalovisio A, Sebag M, Lesokhin A. MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2021. p. S439–S439.